Paul Frohna

Paul Frohna

Auto-generated profile, based on publicly available information

Paul Frohna

ImCheck Therapeutics, 13009 Marseille, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
AGAude De Gassart
Aude De Gassart
KLKieu-Suong Le
Kieu-Suong Le
PBPatrick Brune
Patrick Brune
SASophie Agaugué
Sophie Agaugué
JSJennifer Sims
Jennifer Sims
PFPaul Frohna
Paul Frohna
ICT01, a humanized BTN3A mAb, activates Vγ9Vδ2 T cell antitumor immunity and is well tolerated and pharmacodynamically active in patients.

29 August 2019 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PFPaul A. Frohna
Paul A. Frohna
ARAnoshie Ratnayake
Anoshie Ratnayake
NDNick Doerr
Nick Doerr
ABAsjad Basheer
Asjad Basheer
LALaith Q. Al‐Mawsawi
Laith Q. Al‐Mawsawi
YTYutaka Tagaya
Yutaka Tagaya


1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
WSWilliam Sandborn
William Sandborn
BFBrian G. Feagan
Brian G. Feagan
GDGeert R. D'Haens
Geert R. D'Haens
BLBarrett Levesque
Barrett Levesque
RPRish K. Pai
Rish K. Pai
AOAllan Olson
Allan Olson